HFN Versus NIV in Cystic Fibrosis. The HIFEN Study

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

July 30, 2017

Conditions
Cystic Fibrosis
Interventions
DEVICE

High flow nasal oxygen cannula

HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.

DEVICE

Noninvasive ventilation

The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.

Trial Locations (1)

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
lead

Unity Health Toronto

OTHER

NCT02262871 - HFN Versus NIV in Cystic Fibrosis. The HIFEN Study | Biotech Hunter | Biotech Hunter